120,000 Shares in LifeMD, Inc. (NASDAQ:LFMD) Bought by Courier Capital LLC

Courier Capital LLC bought a new position in LifeMD, Inc. (NASDAQ:LFMD - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 120,000 shares of the company's stock, valued at approximately $653,000. Courier Capital LLC owned about 0.27% of LifeMD as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace LLP grew its position in LifeMD by 522.9% in the fourth quarter. Marshall Wace LLP now owns 371,473 shares of the company's stock valued at $1,839,000 after acquiring an additional 311,841 shares during the period. Royce & Associates LP grew its position in LifeMD by 23.9% in the fourth quarter. Royce & Associates LP now owns 1,115,991 shares of the company's stock valued at $5,524,000 after acquiring an additional 214,950 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in LifeMD by 21.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock valued at $4,610,000 after acquiring an additional 165,378 shares during the period. Renaissance Technologies LLC grew its position in LifeMD by 45.2% in the fourth quarter. Renaissance Technologies LLC now owns 510,000 shares of the company's stock valued at $2,524,000 after acquiring an additional 158,796 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its position in LifeMD by 825.6% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 158,423 shares of the company's stock valued at $784,000 after acquiring an additional 141,307 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at LifeMD

In related news, CMO Jessica Friedeman sold 30,000 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at $962,200. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Justin Schreiber sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $12.47, for a total value of $311,750.00. Following the sale, the chief executive officer now directly owns 2,525,721 shares of the company's stock, valued at $31,495,740.87. This represents a 0.98% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,995 shares of company stock valued at $1,036,172. Corporate insiders own 18.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $14.00 target price on shares of LifeMD in a report on Wednesday, April 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. Finally, B. Riley raised LifeMD to a "strong-buy" rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $11.00.

LifeMD Stock Up 3.9%

Shares of LFMD stock traded up $0.47 during trading on Wednesday, reaching $12.63. 1,954,514 shares of the company's stock were exchanged, compared to its average volume of 1,024,863. The stock has a market capitalization of $574.01 million, a PE ratio of -19.73 and a beta of 2.42. LifeMD, Inc. has a twelve month low of $3.99 and a twelve month high of $13.25. The firm's fifty day moving average price is $8.39 and its 200-day moving average price is $6.61.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million during the quarter, compared to the consensus estimate of $62.47 million. As a group, analysts anticipate that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.